Atika Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Atika Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-34,000	Closed	-$5.82M	–	121
2021 Q1	$5.82M	Sell	34,000 -13,500	-28%	-$2.67M	0.51%	71
2020 Q4	$10.4M	Buy	+47,500	New	+$10.3M	0.82%	59
2019 Q4	–	Sell	-23,000	Closed	-$2.22M	–	91
2019 Q3	$1.79M	Sell	23,000 -24,000	-51%	-$2.25M	0.38%	63
2019 Q2	$4.84M	Buy	+47,000	New	+$3.66M	0.95%	45

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Atika Capital Management's MRTX Position: Q2 2021 in Review

Atika Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 34,000 shares — an estimated $5.82M sold.

Atika Capital Management first reported a position in MRTX in Q2 2019 and held it in 4 quarters. The position peaked at $10.4M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

Atika Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Atika Capital Management sold 34,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5.82M.
Atika Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
Atika Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10.4M in Q4 2020.
245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.